Cyclacel Pharmaceuticals Inc Strategic Asset Allocation Index
Cyclacel Pharmaceuticals Inc strategic asset allocation index. Cyclacel Pharmaceuticals Inc (CYCC) has a Strategic Asset Allocation Index of 1.5% as of June 2023. Strategic assets (PP&E of $148.00K plus long-term investments of $-) total $148.00K, measured against net assets of $9.63 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Cyclacel Pharmaceuticals Inc balance sheet independence to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Cyclacel Pharmaceuticals Inc (2006–2022)
Strategic asset allocation index of Cyclacel Pharmaceuticals Inc from 2006 to 2022. This chart shows how Cyclacel Pharmaceuticals Inc's Strategic Asset Allocation Index has evolved across 17 annual periods from 2006 to 2022. As of June 2023, the index stands at 1.5%, representing strategic assets of $148.00K against net assets of $9.63 Million USD. Check CYCC tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Cyclacel Pharmaceuticals Inc Strategic Asset Allocation Index by Year (2006–2022)
Cyclacel Pharmaceuticals Inc strategic asset allocation index by year from 2006 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Cyclacel Pharmaceuticals Inc from 2006 to 2022, covering 17 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Cyclacel Pharmaceuticals Inc market cap and net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.9% | $174.00K | $174.00K | $- | $20.43 Million | ▲ +0.6 pp |
| 2021 | 0.2% | $94.00K | $94.00K | $- | $37.69 Million | ▼ -0.1 pp |
| 2020 | 0.3% | $106.00K | $106.00K | $- | $33.26 Million | ▲ +0.1 pp |
| 2019 | 0.2% | $27.00K | $27.00K | $- | $11.70 Million | ▼ 0.0 pp |
| 2018 | 0.2% | $36.00K | $36.00K | $- | $15.27 Million | ▲ +0.1 pp |
| 2017 | 0.1% | $29.00K | $29.00K | $- | $21.77 Million | ▼ -0.2 pp |
| 2016 | 0.3% | $45.00K | $45.00K | $- | $14.27 Million | ▼ -0.7 pp |
| 2015 | 1.1% | $198.00K | $198.00K | $- | $18.84 Million | ▼ -0.7 pp |
| 2014 | 1.8% | $387.00K | $387.00K | $- | $21.69 Million | ▲ +0.8 pp |
| 2013 | 1.0% | $275.00K | $275.00K | $- | $28.02 Million | ▼ -0.3 pp |
| 2012 | 1.3% | $129.00K | $129.00K | $- | $10.02 Million | ▲ +0.4 pp |
| 2011 | 0.9% | $167.00K | $167.00K | $- | $19.50 Million | ▼ -0.8 pp |
| 2010 | 1.6% | $408.00K | $408.00K | $- | $24.92 Million | ▼ -17.8 pp |
| 2009 | 19.4% | $901.00K | $901.00K | $- | $4.64 Million | ▲ +10.9 pp |
| 2008 | 8.5% | $1.75 Million | $1.75 Million | $- | $20.64 Million | ▲ +3.3 pp |
| 2007 | 5.2% | $3.02 Million | $3.02 Million | $- | $57.97 Million | ▲ +1.3 pp |
| 2006 | 3.9% | $2.12 Million | $2.12 Million | $- | $53.92 Million | — |